Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
BEIJING, March 01, 2016 -- BeiGene, Ltd. (Nasdaq:BGNE), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced that it will present at the Cowen and Company 36th Annual Health Care Conference in Boston, MA.
John V. Oyler, Founder and Chief Executive Officer, and Howard Liang, Ph.D., Chief Financial Officer and Chief Strategy Officer, will deliver a corporate overview at 2:00 p.m. EST on Monday, March 7, 2016.
A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. With a team of 215+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and a lasting impact on cancer patients.
Media/Investor Contact: Lucy Li, PhD Associate Director of Strategy and Investor Relations 781-801-1800 [email protected] [email protected]
